QLS-101 ophthalmic solution, 2.0 % ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 157 | スタージ・ウェーバー症候群 | 1 |
157. スタージ・ウェーバー症候群
臨床試験数 : 10 / 薬物数 : 13 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05495269 (ClinicalTrials.gov) | November 23, 2022 | 2/8/2022 | Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) | Pilot, Open-label Study of Safety and Tolerability of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) | Sturge-Weber Syndrome;Glaucoma;Ocular Hypertension | Drug: QLS-101 ophthalmic solution, 2.0 % | Qlaris Bio, Inc. | NULL | Active, not recruiting | 12 Years | 19 Years | All | 2 | Phase 2 | United States |